Causal effects of gut microbiota on non-tuberculous mycobacterial lung infection: a bidirectional two-sample mendelian randomization study

doi:10.19982/j.issn.1000-6621.20250292

Abstract

Abstract:

Objective: To assess the causal direction between gut microbiota and non-tuberculous mycobacteria lung infection (NTM-LI). Methods: This study used a bidirectional two-sample Mendelian randomization (MR). Genome-wide association studies (GWAS) data of gut microbiota and NTM-LI were obtained from the GWAS Catalog and the FinnGen databases, respectively. Instrumental variables (IV) were selected based on genome-wide significance thresholds, linkage disequilibrium analysis, and weak instrumental variable screening. The primary causal effect assessed using the inverse-variance weighted (IVW) method, supplemented by using MR-Egger, weighted median, simple mode, and weighted mode methods. Heterogeneity, sensitivity, and horizontal pleiotropy were evaluated using Cochran’s Q test, leave-one-out analysis, MR-Egger intercept test, and MR-PRESSO, respectively. Reverse MR analysis followed the same protocol. Results: IVW analysis revealed that changes in the abundance of specific gut microbiota taxa were significantly associated with the risk of NTM-LI. Odoribacter laneus (OR=1.798, 95%CI: 1.017-3.180, P=0.044), Desulfovibrio piger (OR=1.508, 95%CI: 1.069-2.128, P=0.019) and Blautia hansenii (OR=2.487, 95%CI: 1.222-5.062, P=0.012) could increase the risk of NTM-LI. Conversely, Turicibacteraceae (OR=0.570, 95%CI: 0.343-0.949, P=0.031), RUG420 sp900317985 (OR=0.153, 95%CI: 0.036-0.649, P=0.011), Firmicutes E (OR=0.084, 95%CI: 0.009-0.814, P=0.033), Enteroscipio (OR=0.386, 95%CI: 0.197-0.756, P=0.006), and CAG-145 sp000435615 (OR=0.575, 95%CI: 0.357-0.927, P=0.023) could reduce the risk of NTM-LI. No significant heterogeneity, horizontal pleiotropy, and outlier interference was detected. Furthermore, reverse MR analysis did not support effect of NTM-LI on gut microbiota composition. Conclusion: This MR analysis reveals a potential causal relationship between specific gut microbiota and NTM-LI. Targeted modulation of these specific gut microbial taxa holds promise as a novel intervention strategy for the prevention and treatment of NTM-LI.

Key words: Gut microbiota, Mycobacterium infections, Lung diseases, Causality, Mendelian randomization

CLC Number:

R563

Tan Xiao, Li Fangping, Zhang Qian, Zhang Meijia. Causal effects of gut microbiota on non-tuberculous mycobacterial lung infection: a bidirectional two-sample mendelian randomization study[J]. Chinese Journal of Antituberculosis, 2026, 48(1): 121-130. doi: 10.19982/j.issn.1000-6621.20250292

Figures/Tables 9

References 43

[1]	鲍容, 沈佳瑾, 陈裕, 等. 综合性医院非结核分枝杆菌菌种分布及其耐药性. 中华医院感染学杂志, 2025, 35(2): 202-206. doi:10.11816/cn.ni.2025-248493.
[2]	储美萍, 钱静娟, 程亮, 等. 非结核分枝杆菌病临床特征及临床分离株的菌种分布及耐药性. 中华医院感染学杂志, 2024, 34(1): 41-44. doi:10.11816/cn.ni.2024-230785.
[3]	Cristancho-Rojas C, Varley CD, Lara SC, et al. Epidemiology of Mycobacterium abscessus. Clin Microbiol Infect, 2024, 30(6):712-717. doi:10.1016/j.cmi.2023.08.035.
[4]	Singh K, Kumari R, Tripathi R, et al. Detection of clinically important non tuberculous mycobacteria (NTM) from pulmonary samples through one-step multiplex PCR assay. BMC Microbiol, 2020, 20(1): 267. doi:10.1186/s12866-020-01952-y. pmid: 32847517
[5]	张良登, 冯兴中, 姜敏, 等. 基于肺与大肠相表里的肺病患者肠道便菌群特点研究. 中国中医药信息杂志, 2018, 25(4):19-23. doi:10.3969/j.issn.1005-5304.2018.04.005.
[6]	Enaud R, Hooks KB, Barre A, et al. Intestinal Inflammation in Children with Cystic Fibrosis Is Associated with Crohn’s-Like Microbiota Disturbances. J Clin Med, 2019, 8(5):645. doi:10.3390/jcm8050645.
[7]	Hu Y, Feng Y, Wu J, et al. The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients. Front Cell Infect Microbiol, 2019, 9:90. doi:10.3389/fcimb.2019.00090.
[8]	李寒雪, 张瑶, 马燕. “肺-肠轴”理论下肠道菌群与肺动脉高压炎症机制的研究进展. 中国慢性病预防与控制, 2025, 33(5): 385-390. doi:10.16386/j.cjpccd.issn.1004-6194.20240717.0527.
[9]	毛振南, 杨占东. 肠道菌群在慢性阻塞性肺疾病中的作用. 生理科学进展, 2025, 56(1): 30-38. doi:10.20059/j.cnki.pps.2024.12.1233.
[10]	何嘉伟, 毛宁锋, 赵毅, 等. 基于“肺与大肠相表里”探讨肠道菌群和下呼吸道感染的因果关联:一项双样本孟德尔随机化研究. 中华中医药杂志, 2024, 39(12): 6678-6683.
[11]	孔令宜, 王园园, 缪长宏, 等. 肠道微生物与细菌性肺炎易感性的因果关系:双样本双向孟德尔随机化研究及cML-MA的应用. 中国急救医学, 2024, 44(2):148-155. doi:10.3969/j.issn.1002-1949.2024.02.009.
[12]	Carroll KC, Adams LL. Lower Respiratory Tract Infections. Microbiol Spectr, 2016, 4(4). doi:10.1128/microbiolspec.DMIH2-0029-2016.
[13]	周望展, 何卫, 张颖. 某医院住院患者下呼吸道感染的病原体分布及流行病学特征. 中华医院感染学杂志, 2025, 35(18): 2741-2745. doi:10.11816/cn.ni.2025-250372.
[14]	全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012, 34(8): 485-508.
[15]	Kim YJ, Lee JY, Lee JJ, et al. Arginine-mediated gut microbiome remodeling promotes host pulmonary immune defense against nontuberculous mycobacterial infection. Gut Microbes, 2022, 14(1):2073132. doi:10.1080/19490976.2022.2073132.
[16]	Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med, 2008, 27(8):1133-1163. doi:10.1002/sim.3034. pmid: 17886233
[17]	Lu J, Lin Y, Jiang J, et al. Investigating the potential causal association between consumption of green tea and risk of lung cancer: a study utilizing Mendelian randomization. Front Nutr, 2024, 11:1265878. doi:10.3389/fnut.2024.1265878.
[18]	Tang F, Wang S, Zhao H, et al. Mendelian randomization analysis does not reveal a causal influence of mental diseases on osteoporosis. Front Endocrinol (Lausanne), 2023, 14: 1125427. doi:10.3389/fendo.2023.1125427.
[19]	Balavoine C, Andréjak C, Marchand-Adam S, et al. Relationships between COPD and nontuberculous mycobacteria pulmonary infections. Rev Mal Respir, 2017, 34(10):1091-1097. doi:10.1016/j.rmr.2017.09.004. pmid: 29150178
[20]	Honda JR, Alper S, Bai X, et al. Acquired and genetic host susceptibility factors and microbial pathogenic factors that predispose to nontuberculous mycobacterial infections. Curr Opin Immunol, 2018, 54:66-73. doi:10.1016/j.coi.2018.06.001. pmid: 29936307
[21]	张晓萌, 李敏, 柴英辉, 等. 肠道菌群短链脂肪酸与肺结核相关性研究进展. 中国防痨杂志, 2023, 45(7): 699-706. doi:10.19982/j.issn.1000-6621.20230079.
[22]	杨艳青, 李灿委, 杨自忠, 等. 肠道菌群代谢物——短链脂肪酸的研究进展. 实用医学杂志, 2022, 38(14): 1834-1837. doi:10.3969/j.issn.1006-5725.2022.14.023.
[23]	Lin TL, Kuo YL, Lai JH, et al. Gut microbiota dysbiosis-related susceptibility to nontuberculous mycobacterial lung disease. Gut Microbes, 2024, 16(1):2361490. doi:10.1080/19490976.2024.2361490.
[24]	Tiffany CR, Lee JY, Rogers AWL, et al. The metabolic footprint of Clostridia and Erysipelotrichia reveals their role in depleting sugar alcohols in the cecum. Microbiome, 2021, 9(1):174. doi:10.1186/s40168-021-01123-9. pmid: 34412707
[25]	Di Modica M, Gargari G, Regondi V, et al. Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer. Cancer Res, 2021, 81(8):2195-2206. doi:10.1158/0008-5472.CAN-20-1659.
[26]	Rowan S, Taylor A. Gut microbiota modify risk for dietary glycemia-induced age-related macular degeneration. Gut Microbes, 2018, 9(5):452-457. doi:10.1080/19490976.2018.1435247. pmid: 29431583
[27]	Vich Vila A, Imhann F, Collij V, et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med, 2018, 10(472): eaap8914. doi:10.1126/scitranslmed. aap8914.
[28]	Ma J, Zhu Z, Yishajiang Y, et al. Role of gut microbiota and inflammatory factors in acute respiratory distress syndrome: a Mendelian randomization analysis. Front Microbiol, 2023, 14:1294692. doi:10.3389/fmicb.2023.1294692.
[29]	Cheng ZX, Hua JL, Jie ZJ, et al. Genetic Insights into the Gut-Lung Axis: Mendelian Randomization Analysis on Gut Microbiota, Lung Function, and COPD. Int J Chron Obstruct Pulmon Dis, 2024, 19:643-653. doi:10.2147/COPD.S441242.
[30]	热西丁·阿不都艾尼. 毛螺菌科的定向分离培养与其代谢组学特性研究. 北京: 中国科学院大学, 2022.
[31]	Dora D, Weiss GJ, Megyesfalvi Z, et al. Computed Tomography-Based Quantitative Texture Analysis and Gut Microbial Community Signatures Predict Survival in Non-Small Cell Lung Cancer. Cancers (Basel), 2023, 15(20):5091. doi:10.3390/cancers15205091.
[32]	Song P, Yang D, Wang H, et al. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. Thorac Cancer, 2020, 11(6):1621-1632. doi:10.1111/1759-7714.13442. pmid: 32329229
[33]	Sun Y, Zhang S, Nie Q, et al. Gut firmicutes: Relationship with dietary fiber and role in host homeostasis. Crit Rev Food Sci Nutr, 2023, 63(33): 12073-12088. doi:10.1080/10408398.2022.2098249.
[34]	肖祥, 吴宣諭, 韩洁榕, 等. “肺与大肠相表里”视角下探索肠道菌群与肺癌因果关联及潜在干预中药预测. 中草药, 2024, 55(12): 4108-4120. doi:10.7501/j.issn.0253-2670.2024.12.018.
[35]	Huber-Ruano I, Calvo E, Mayneris-Perxachs J, et al. Orally administered Odoribacter laneus improves glucose control and inflammatory profile in obese mice by depleting circulating succinate. Microbiome, 2022, 10(1):135. doi:10.1186/s40168-022-01306-y. pmid: 36002880
[36]	Lee SB, Gupta H, Min BH, et al. A consortium of Hordeum vulgare and gut microbiota against non-alcoholic fatty liver disease via data-driven analysis. Artif Cells Nanomed Biotechnol, 2024, 52(1):250-260. doi:10.1080/21691401.2024.2347380.
[37]	Nguyen SM, Tran HTT, Long J, et al. Gut microbiome in association with chemotherapy-induced toxicities among patients with breast cancer. Cancer, 2024, 130(11):2014-2030. doi:10.1002/cncr.35229. pmid: 38319284
[38]	Gou Y, Lin F, Dan L, et al. Exposure to toluene diisocyanate induces dysbiosis of gut-lung homeostasis: Involvement of gut microbiota. Environ Pollut, 2024, 363(Pt 1):125119. doi:10.1016/j.envpol.2024.125119.
[39]	Fan L, Chen J, Zhang Q, et al. Fecal microbiota transplantation for hypertension: an exploratory, multicenter, randomized, blinded, placebo-controlled trial. Microbiome, 2025, 13(1):133. doi:10.1186/s40168-025-02118-6.
[40]	Wang Y, Zhang Y, Lane NE, et al. Population-based metagenomics analysis reveals altered gut microbiome in sarcopenia: data from the Xiangya Sarcopenia Study. J Cachexia Sarcopenia Muscle, 2022, 13(5):2340-2351. doi:10.1002/jcsm.13037. pmid: 35851765
[41]	Shibata M, Ozato N, Tsuda H, et al. Mouse Model of Anti-Obesity Effects of Blautia hansenii on Diet-Induced Obesity. Curr Issues Mol Biol, 2023, 45(9):7147-7160. doi:10.3390/cimb45090452. pmid: 37754236
[42]	Ozato N, Yamaguchi T, Mori K, et al. Two Blautia Species Associated with Visceral Fat Accumulation: A One-Year Longitudinal Study. Biology (Basel), 2022, 11(2):318. doi:10.3390/biology11020318.
[43]	Jia Y, He T, Wu D, et al. The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota. J Transl Med, 2022, 20(1):281. doi:10.1186/s12967-022-03481-w. pmid: 35729584

暴露/结局	数据来源	样本数(例)	样本来源	数据下载链接
肠道菌群	FINRISK 2002	5959	欧洲人种	https://www.ebi.ac.uk/gwas/
非结核分枝杆菌肺病	The FinnGen Biobank	483557	欧洲人种	https://www.finngen.fi/en

肠道菌群	方法	单核苷酸多态性(个)	P值	OR(95%CI)值
苏黎世杆菌科	IVW	18	0.031	0.570(0.343~0.949)
	MR-Egger	18	0.430	0.615(0.189~2.000)
	WME	18	0.164	0.626(0.323~1.211)
	SM	18	0.666	0.760(0.224~2.581)
	WM	18	0.725	0.818(0.272~2.457)
RUG420 sp900317985	IVW	17	0.011	0.153(0.036~0.649)
	MR-Egger	17	0.040	0.018 (0.000~0.599)
	WME	17	0.047	0.125(0.016~0.970)
	SM	17	0.173	0.056(0.001~2.927)
	WM	17	0.206	0.063(0.001~3.843)
厚壁菌门E	IVW	19	0.033	0.084(0.009~0.814)
	MR-Egger	19	0.998	0.995(0.006~163.499)
	WME	19	0.299	0.201(0.010~4.150)
	SM	19	0.486	0.138(0.001~32.230)
	WM	19	0.466	0.138(0.001~25.124)
人肠道杆菌属	IVW	24	0.006	0.386(0.197~0.756)
	MR-Egger	24	0.373	0.445(0.077~2.553)
	WME	24	0.052	0.431(0.185~1.006)
	SM	24	0.281	0.429(0.096~1.924)
	WM	24	0.225	0.408(0.100~1.670)
CAG-145 sp000435615	IVW	19	0.023	0.575(0.357~0.927)
	MR-Egger	19	0.413	0.642(0.227~1.810)
	WME	19	0.134	0.614(0.324~1.163)
	SM	19	0.534	0.668(0.192~2.324)
	WM	19	0.552	0.679(0.194~2.377)

肠道菌群	方法	单核苷酸多态性(个)	P值	OR(95%CI)值
羊毛状臭气杆菌	IVW	24	0.044	1.798(1.017~3.180)
	MR-Egger	24	0.806	1.161(0.358~3.766)
	WME	24	0.172	1.674(0.799~3.505)
	SM	24	0.519	1.690(0.351~8.126)
	WM	24	0.467	1.690(0.421~6.782)
懒惰脱硫弧菌	IVW	24	0.019	1.508(1.069~2.128)
	MR-Egger	24	0.119	1.849(0.879~3.887)
	WME	24	0.342	1.262(0.781~2.041)
	SM	24	0.595	1.260(0.544~2.917)
	WM	24	0.662	1.232(0.488~3.110)
汉氏布劳特氏菌	IVW	19	0.012	2.487(1.222~5.062)
	MR-Egger	19	0.017	6.986(1.666~29.299)
	WME	19	0.007	3.740(1.445~9.680)
	SM	19	0.072	5.006(0.959~26.129)
	WM	19	0.083	4.704(0.901~24.574)

暴露	MR-Egger截距	多效性检验P值	MR-PRESSO全局检验P值
苏黎世杆菌科	-0.009	0.891	0.981
RUG420 sp900317985	0.085	0.208	0.461
厚壁菌门E	-0.065	0.304	0.923
人肠道杆菌属	-0.011	0.866	0.139
CAG-145 sp000435615	-0.014	0.818	0.977
羊毛状臭气杆菌	0.047	0.413	0.355
懒惰脱硫弧菌	-0.033	0.551	0.982
汉氏布劳特氏菌	-0.098	0.126	0.392

暴露	Cochrane Q值	异质性检验P值	暴露	Cochrane Q值	异质性检验P值
苏黎世杆菌科	7.718	0.518	CAG-145 sp000435615	8.236	0.975
RUG420 sp900317985	16.041	0.370	羊毛状臭气杆菌	25.711	0.315
厚壁菌门E	10.111	0.928	懒惰脱硫弧菌	11.610	0.976
人肠道杆菌属	31.511	0.111	汉氏布劳特氏菌	19.367	0.370